Peptide half-life is the time it takes for the amount of a peptide in the body, usually measured in the blood, to fall by half. Many natural peptides have half-lives of only minutes, because enzymes break them down and the kidneys clear them quickly. Scientists have developed several ways to extend half-life, which is why some modified peptides last hours or even about a week. This guide explains the concept, the biology behind it, and the common misunderstandings.
Key Takeaways
- Elimination half-life is the time needed for the concentration of a substance in the body to fall to half of its starting value [1].
- Natural peptides often have very short half-lives because of enzymatic breakdown and rapid kidney clearance [2][3].
- Native GLP-1 has a half-life of about 1.5 minutes after intravenous dosing in humans [4]. The modified analog semaglutide has a half-life of about one week, according to its EU product information [5].
- Common half-life extension strategies include D-amino acid substitution, end-group modifications, PEGylation, and albumin binding [2][4][6].
- Half-life in the body is different from shelf life or stability in a vial.
- Half-lives measured in animals often differ from those in humans [4][5].
What Does Half-Life Mean?
In pharmacology, "half-life" usually means elimination half-life: the time required for the concentration of a substance, typically a drug, to decrease to half of its initial amount in the body [1]. After one half-life, 50% is gone. After another, half of the remainder is gone, and so on.
Most drugs follow first-order kinetics, meaning the elimination rate is proportional to the concentration. A few, such as ethanol, follow zero-order kinetics, in which a constant amount is removed per unit of time regardless of concentration [1].
For first-order elimination, the arithmetic looks like this:
| Half-lives elapsed | Fraction remaining |
|---|---|
| 0 | 100% |
| 1 | 50% |
| 2 | 25% |
| 3 | 12.5% |
| 4 | 6.25% |
| 5 | about 3% |
This is why a substance with a half-life of about one week can remain detectable for weeks. The EU product information for semaglutide states that, with an elimination half-life of about one week, it will be present in the circulation for about five weeks after the last dose [5].
Why Natural Peptides Have Short Half-Lives
1. Enzymes cut them apart
The body contains many proteases and peptidases, enzymes that cleave peptide bonds. Enzymatic degradation during circulation is one of the main reasons peptides and proteins have short plasma half-lives [2]. Because most short peptides lack a protective folded structure, their bonds are exposed [6].
The classic example is GLP-1. It is inactivated extremely rapidly by the enzyme dipeptidyl peptidase-IV (DPP-IV), even before the hormone leaves the gut [7].
2. The kidneys filter them out
Fast renal (kidney) clearance is the other major cause of short plasma half-lives [2]. Small molecules pass through the kidney's filters more easily than large ones. This is why several half-life extension strategies work by making the peptide effectively bigger [6].
3. Other ADME factors
Pharmacologists describe a molecule's journey with the acronym ADME: absorption, distribution, metabolism, and excretion. A review by Di (2015) summarizes that natural peptides typically have poor ADME properties, including rapid clearance, short half-life, low permeability, and sometimes low solubility [3].
For more on how peptides act before they are cleared, see How Peptides Work in the Body.
Real Examples of Peptide Half-Life
| Molecule | Reported half-life | Source |
|---|---|---|
| Native GLP-1 | About 1.5 minutes (intravenous) and 1.5 hours (subcutaneous) in humans | Knudsen & Lau, 2019 [4] |
| Somatostatin | A few minutes | Werle & Bernkop-Schnürch, 2006 [2] |
| Octreotide (a shortened somatostatin analog containing D-amino acids) | About 1.5 hours | Werle & Bernkop-Schnürch, 2006 [2] |
| Semaglutide | About 1 week | EU Summary of Product Characteristics [5] |
These examples show how much structure matters. Octreotide was created by shortening somatostatin and replacing some L-amino acids with D-amino acids, which extended its plasma half-life from minutes to about 1.5 hours [2].
Note the GLP-1 row: the route matters. The same peptide showed a much longer apparent half-life after injection under the skin than after intravenous dosing [4], because absorption from the injection site takes time.
How Scientists Extend Peptide Half-Life
Half-life extension is one of the central themes of peptide drug design. A 2020 review of GPCR-targeting peptide drugs described half-life-extending modifications as "revolutionary" [8]. Common strategies include:
D-amino acids and unnatural amino acids
Swapping natural L-amino acids for D-forms or other unnatural amino acids, especially at sites where enzymes cut, can extend plasma half-life [2][6]. There is a trade-off: a 2022 review notes that D-amino acid changes can reduce biological activity [6].
End (terminal) modifications
Chemically modifying the N-terminus or C-terminus (the two ends of the chain) is another established strategy for prolonging plasma half-life [2].
PEGylation
Attaching polyethylene glycol (PEG) chains increases a molecule's effective size, reducing kidney filtration, and shields it from enzymes [6]. For example, a PEGylated form of interferon alfa-2b showed a 330-fold longer plasma half-life than the native protein [2].
Albumin binding
Albumin, the most abundant protein in blood plasma, has a half-life of several weeks [4]. Attaching a fatty acid to a peptide lets it bind reversibly to albumin, which protects it from DPP-IV breakdown and from kidney filtration. This approach was used to design the long-acting GLP-1 analogs liraglutide and semaglutide [4]. The EU product information for semaglutide identifies albumin binding as the principal mechanism of its prolonged action, via decreased renal clearance and protection from metabolic degradation [5].
Animal Half-Life Is Not Human Half-Life
Half-life can differ dramatically between species. During semaglutide's development, its half-life in rats was around 7 hours [4], while in humans it is about one week [5]. Researchers also saw differences between rats and minipigs when comparing related molecules [4].
This is one reason animal results should not be assumed to translate directly to humans. Read more in How to Judge Peptide Research.
Half-Life vs. Shelf Life vs. Stability
People often confuse three different ideas:
- Half-life (in the body): how quickly the body eliminates a substance [1].
- Shelf life or retest period: how long a stored material stays within its quality specifications. Regulators expect this to be supported by formal stability studies [9].
- Chemical stability: how resistant a molecule is to degradation, such as oxidation, deamidation, or hydrolysis, during manufacture and storage [9].
A peptide can be quite stable as a dry powder in a freezer yet have a half-life of minutes in the bloodstream, or the reverse. To learn about storage-related stability, see Peptide Storage: Temperature, Light, and Moisture and How Peptides Degrade.
Frequently Asked Questions
What is the half-life of a peptide?
It varies enormously, from minutes for many natural peptides such as GLP-1 and somatostatin to about a week for heavily modified analogs such as semaglutide [2][4][5].
Why do peptides have short half-lives?
Mainly because enzymes cleave their peptide bonds and the kidneys clear them rapidly [2][3].
How many half-lives until a substance is eliminated?
Under first-order kinetics, about 3% remains after five half-lives (half of a half, five times over). The EU product information for semaglutide, for example, says it remains in circulation for about five weeks after the last dose, given a half-life of about one week [5].
Does half-life tell you how long a peptide lasts in a vial?
No. Half-life describes elimination from the body. Storage stability and shelf life are separate properties that are measured in formal stability studies [9].
How do scientists make peptides last longer in the body?
Common approaches include D-amino acid substitution, terminal modifications, PEGylation, and fatty-acid-mediated albumin binding [2][4][6].
References
- Hallare J, Gerriets V. Elimination Half-Life of Drugs. In: StatPearls. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554498/ ↗ (PubMed: https://pubmed.ncbi.nlm.nih.gov/32119385/ ↗)
- Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351–367. https://doi.org/10.1007/s00726-005-0289-3 ↗
- Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17(1):134–143. https://doi.org/10.1208/s12248-014-9687-3 ↗
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. https://doi.org/10.3389/fendo.2019.00155 ↗
- European Medicines Agency. Ozempic (semaglutide): EPAR – Product Information (Summary of Product Characteristics), sections 4.6, 4.9, and 5.2. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf ↗
- Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7(1):48. https://doi.org/10.1038/s41392-022-00904-4 ↗
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439. https://doi.org/10.1152/physrev.00034.2006 ↗
- Davenport AP, Scully CCG, de Graaf C, Brown AJH, Maguire JJ. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020;19(6):389–413. https://doi.org/10.1038/s41573-020-0062-z ↗
- European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025), section 4.7 (Stability). https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline ↗
Educational disclaimer: This article is for general educational purposes only. It is not medical, legal, or regulatory advice, and it does not recommend or describe the use of any product. Half-life figures are cited to explain a scientific concept, not to guide use. For health questions, consult a qualified healthcare professional. For regulatory questions, consult the relevant regulatory authority in your jurisdiction.